• Wellgistics Health, Inc. (NASDAQ:WGRX) saw a 168.16% increase, potentially driven by its blockchain initiative in prescription drug tracking.
• MaxsMaking Inc. (NASDAQ:MAMK) experienced a 148.70% rise following its successful IPO, highlighting investor interest in its innovative textile production.
• Inhibrx Biosciences, Inc. (NASDAQ:INBX) surged 94.43%, possibly due to positive developments in its clinical trials for a rare bone cancer treatment.

In the latest market movements, several companies have shown significant price changes, reflecting various underlying factors that have influenced their stock performance. Here's a consolidated analysis of the top gainers based on the provided data:

Wellgistics Health, Inc. (NASDAQ:WGRX) experienced a remarkable surge, with its price jumping to $1.08, marking a 168.16% increase. This pharmaceutical wholesaler and distributor has been actively trading, with volume reaching over 614 million, significantly higher than its average. The company's focus on distributing generic and branded pharmaceuticals, along with its third-party logistics services, might be driving investor interest, especially considering the healthcare sector's resilience and growth potential. As highlighted by Invezz, the surge follows the announcement of a non-binding letter of intent with Datavault AI Inc. (NASDAQ:DVLT) to integrate blockchain-enabled smart contracts into its prescription drug tracking system, under the initiative named “PharmacyChain.”

MaxsMaking Inc. (NASDAQ:MAMK), a China-based manufacturer of customized consumer textile goods, saw its price escalate to $7.43, a 148.70% rise. The company's innovative use of proprietary systems for efficient production could be attracting investor attention, reflected in the volume of over 1.4 million. The significant price movement indicates a strong market response to either company developments or broader industry trends. This rise coincides with the successful closing of its initial public offering, raising $6.5 million, with shares beginning trading on the Nasdaq Capital Market on July 7, 2025.

Inhibrx Biosciences, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company, witnessed its stock price soar to $55.13, up by 94.43%. With a focus on developing biologic therapeutics for life-threatening conditions, Inhibrx's progress in its clinical trials or strategic partnerships could be factors contributing to this impressive growth. The trading volume of over 5 million suggests heightened investor interest, possibly due to recent positive developments or announcements. The surge follows the announcement that its experimental drug effectively slowed the progression of a rare and aggressive bone cancer in a mid-stage trial.

Genenta Science S.p.A. (NASDAQ:GNTA), engaged in developing hematopoietic stem cell gene therapies, saw its stock price increase to $6.22, a 92.72% jump. The company's innovative approach to treating solid tumors might be gaining traction among investors, as indicated by the trading volume of over 20 million. This surge could be attributed to promising clinical trial results or strategic collaborations that have recently come to light. Genenta Science and ANEMOCYTE have entered into a strategic partnership to advance off-the-shelf lentiviral vector (LVV) Plasmid DNA production, building on their existing successful partnership.

These movements reflect a diverse range of sectors, from healthcare and biotechnology to consumer goods and technology, indicating varied investor interest and market dynamics. Factors such as clinical trial outcomes, strategic partnerships, innovative product offerings, and market trends could be driving these significant price changes. Investors and market watchers will likely keep a close eye on these companies for further developments that could influence their stock performance.